Chronicle of events
Beginning in 1993, 3SBio dares to innovate and pursues excellence. After 20 years of rapid development, 3SBio Group has now become a leading Chinese biopharmaceutical company that integrates R&D, production and sales, and has achieved great success in the international market.
-
1993
Shenyang Sunshine Pharmaceuticals Co., Ltd. was established.
In 1993, Shenyang Sunshine Pharmaceuticals CO., Ltd was founded by the 58-year-old Major General Lou Dan and his team. Lou Dan is a member of the National Medical Review Committee, a well-known bioengineering medical expert and the previous director of the Institute of Microbiology and Immunology of Shenhou Military Medical Research Institute and served as the chairman and president as well as chief engineer of the company.
-
1995
In 1995, Intefen (recombinant human interferon α2a injection) was launched. In 2000, Mr Lou Dan, founder of the company, first proposed that “To make the Interferon as affordable as penicillin for ordinary people”, whipping up price reduction storm in the bio-pharmaceutical industries
In April 1995, Intefen was approved to be manufactured by NMPA.
In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug. -
1996
Inleusin (recombinant human interleukin-2 for injection) was listed
In June 1995, NMPA production approval documents were obtained for Inleusin.
This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.
-
1998
EPIAO (recombinant human erythropoietin injection (CHO cell)) was listed, which was one of the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market
In 1998, EPIAO was marketed with approval of the NMPA, which was the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market. It is included in the National Medical Insurance Catalogue as a Category B drug.
-
2002
In 2002, SEPO (recombinant human erythropoietin injection (CHO cell)) and SPARIN (injectable low-molecular-weight heparin calcium) were listed and included in the product team of the Group in 2014
NMPA production approval documents were obtained for SEPO in 2001.It was listed in 2002 and is included in the National Medical Insurance Catalogue as a Category B drug. In 2014, SEPO was rated as famous trademark by Guangdong Province Administration for Industry & Commerce. SPARIN was approved by the NMPA and listed in 2002.
-
2005
Co-founder Dr. Lou Jing led the research and development of TPIAO as a new class of Chinese medicine (recombinant human thrombopoietin injection), which was listed and the only commercial platelet-derived growth factor in the world
In 2005, TPIAO was listed and has been approved by the NMPA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
The first antibody fusion protein in China, YISAIPU (recombinant human tumor necrosis factor-α receptor Ⅱ: IgG-Fc fusion protein for injection) was listed, and was included in the product team of the Group in 2016
YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 2 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
-
2006
Through Sunshine (Liaoning), we obtained the exclusive right to the distribution of iron sucrose injection.
-
2007
It is listed on NASDAQ
-
2009
Qiming granule (National protected traditional Chinese medicines) was listed for treatment of type II diabetic retinopathy simplex and was included in the product team of the Group in 2015
Qiming granule is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy.
It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by NMPA in 2013. Qiming granule is the first NMPA-approved new Chinese medicine for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.
-
2010
We completed the construction of additional production facilities for EPIAO and TPIAO in Shenyang Economic and Technological Development Zone.
These facilities have been certified by NMPA and comply with the major international regulatory guidelines (including regulations of the cooperation plan between European Food and Drug Administration and International Drug Inspection).These facilities have increased the production capacity of EPIAO and TPIAO by approximately four times.
-
2011
NMPA approved that we voluntarily upgrade product quality manufacturing standards of EPIAO to full compliance with European Pharmacopoeia standards.
-
2013
The company was privatized by the buyer group led by management and CITIC PE, and was delisted from NASDAQ.
-
2014
we acquired the Sciprogen Bio-pharmaceutical Co.,Ltd. based in China.
We also acquired Sirton, a contract drug manufacturer based in Italy.
We separately entered into a strategic cooperation agreement with CPGJ, and acquired approximately 6.96% of stock rights from CPGJ.
-
2015
Qiming granule was incorporated into the company's product group.
Qiming granule is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy.
It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by NMPA in 2013.Qiming granule is the first NMPA-approved new TCM drug for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.
The company was listed on Hong Kong Stock Exchange, acquired Zhejiang Wansheng Pharmaceutical Co., Ltd. and was included in the Hang Seng Composite Large and Medium Stock Index.
-
2016
3SBio reached business cooperation with AstraZeneca. GLP-1 receptor agonists Byetta (exenatide injection) and BydureonTM (exenatide sustained-releasing drug) were included in the product team of the Group for improving the glycemic control in patients with type II diabetes.
On October 11, 2016, we have entered into an exclusive license agreement with AstraZeneca to obtain the commercial rights of Byetta and Bydureon in China, which are valid for 20 years.
3SBio opened the strategic layout of collectivization, becoming the only bio-pharmaceutical enterprise shortlisted for TOP 100 Enterprises of Chinese Pharmaceutical Industry, and ranking the top 20 of Chinese Pharmaceutical R&D. It held 97.8% CPGJ shares and was included in the MSCI China Index
-
2017
TPIAO, YISAIPU and Qiming granule were included in 2017 Medical Insurance Catalogue; Signed the exclusive license agreement with Lilly for insulin product Humuli; Raised 300 million Euros by issuing convertible bonds.
-
2019
The humanized anti-CD25 monoclonal antibody drug Xenopax developed independently by Sunshine Guojian, an affiliate with 3SBio Group, has been granted the GMP certificate by the NMPA, and it will be used to prevent acute rejection after kidney transplantation.
-
2020
Cipterbin ( Inetetamab for Injection), the first innovative anti-HER2 monoclonal antibody independently developed by Sunshine Guojian, an affiliate with 3SBio Group, has been approved by the NMPA. In combination with chemotherapy drugs, it can significantly reduce the risk of disease progression in patients with HER2-positive metastatic breast cancer, improve the objective response rate, and prolong the progression-free survival of the patients.
-
2021
3SBio Mandi tops the sales list of OTC drugs in Alibaba Health pharmacy and JD skin-care dept during “618”, “Double 11” shopping frenzy, while ranked No.4 among OTC dermatology drugs.
December 2021, 3SBio established CDMO platform SIGO Shanghai, developing customized CDMO service.
-
2022
The global right of the anti-PD-1 mAb (609A) proprietarily, developed by Sunshine Guojian, an affiliate with 3SBio Group, for specific combination therapy (tumor immunotherapy Syncrovax™) was granted to Syncromune Inc. in the U.S.. According to the agreement, Sunshine Guojian may receive payments totaling several hundreds of millions of USD including an upfront payment, milestone payments, and other incentives.